STUDY OF CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS ('E' NEGATIVE) WITH VIRAL LOAD AROUND 10,000 COPIES/ML AND NORMAL OR BORDERLINE AST/ALT ELEVATIONAT A TERTIARY CARE HOSPITAL IN CHENNAI

Main Article Content

Dr. Deepak Anand R.
Dr. Sabariselvan C.

Keywords

Chronic Hepatitis B Virus, Infected Patients ('e' negative), Viral Load, Normal or Borderline AST/ALT Elevation

Abstract

Background: This study was conducted to examine patients who were chronically infected with the hepatitis B virus ('e' negative), with a viral load of around 10,000 copies/ml and normal to borderline elevated AST/ALT levels.


Methods: 43 chronic HBV-infected patients at Southern Railway Headquarters Hospital, Aynavaram, Chennai, participated in this hospital-based cross-sectional study from June 2011 to May 2013, with written informed consent from study participants and approval from the institutional ethics committee.


Results: When performing a correlation analysis, at the 0.05 level (2-tailed), the correlation is significant; at the 0.01 level (2-tailed), the correlation is significant. The minimum observed test value minus one is the smallest cut-off value in the ROC curve (PCR coordinates), while the maximum observed test value plus one is the greatest cut-off value. The remaining cut-off values are the averages of two consecutively ordered observed test values. There is at least one tie between the positive actual state group and the negative actual state group in the ROC curve's alt coordinates. a. The greatest observed test value plus one is the biggest cut-off value; the smallest cut-off value is the least observed test value minus one. The averages of two consecutively ordered observed test values are used to determine all other cut-off values. The test result variable(s): ALT has at least one tie between the positive actual state group and the negative actual state group in the area under the ROC curve comparison between alt and PCR. There could be bias in the statistics. a) Assuming nonparametric data; b) True area = 0.5 is the null hypothesis.


Conclusion: In order to distinguish between inactive carriers and e-negative chronic HBV infection, liver biopsy is essential in patients with normal AST/ALT and HBV DNA levels of approximately 105 copies/ml. Since ALT seems to have a stronger correlation with necro-inflammatory activity, periodic monitoring of it is essential.

Abstract 26 | Pdf Downloads 18

References

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337(24):1733-45.
2. Chen DS. Toward elimination and eradication of hepatitis-B. J Gastroenterol Hepatol 2010;25(1):19-25.
3. Anonymous. World Health Organisation, Department of Communicable Disease. Surveillance and Response Hepatitis B. 2002. Report No. WHO/CSR/LYO/2002.2.
4. Puri P, Srivastava S. Lower chronic Hepatitis b in south Asia despite all odds: bucking the trend of other infectious diseases. Trop Gasteroenterol 2012;33(2):89-94.
5. Kant L, Hall AJ. Epidemiology of childhood hepatitis in India: Vaccination related issues. Indian Journal of Paediatrics 1995; 62:635-53.
6. Sarin SK, Kumar M. HBV prevalence, natural history, and treatment in India and Indian Americans in United States. Current Hepatitis Reports 2009; 8:31-8.
7. Arora U, Mann A. Prevalence of hepatitis-B virus, hepatitis C virus, and HIV in patients with chronic liver disease in Amritsar. JIACM 2007;8(1):29-37.
8. Khan MA, Ashraf M, Rehman A, Ali A, Ashraf M, Ditta A. Prevalence of HBV, HCV, HIV in Blood Donors at Liyaqatpur. Professional Medical Journal 2006;13(1):23-6.
9. Kunnathuparambil SG, Zameer M, Sathar SA, Sreesh S, Madhavan M, Devadas K,et al. 3 Clinical, biochemical, and virological parameters in the differentiation of acute hepatitis b from chronic hepatitis b with flare. Journal of Clinical and Experimental Hepatology 2012;2(1):S7.
10. Dutta S. An overview of molecular epidemiology of Hepatitis B Virus in India. Virol J 2008; 5:156.
11. World Health Organization. Introducing Hepatitis B vaccine to Universal Immunization Programme in India. A Brief Scenario. 2012. Available from
http://www.whoindia.org/en/section6/section8.htm
12. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001;120(7):1828-53.
13. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen negative chronic hepatitis B. Hepatology 2001;34(4):617-24.
14. Hunt CM, McGill JM, Allen ML, Condreay LD. Clinical relevance of hepatitis B virus mutations. Hepatology 2000;31(5):1037-44.
15. Bonino F, Rosina F, Rizzetto M, Rizzi R, Chiaberge E, Tardanico R, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986;90(5):1268-73.
16. Brunetto MR, Giarin M, Oliveri F, Chiaberge E, Baldi M, Alfarano A, et al. Wild type and e antigen-minus hepatitis B virus in course of chronic hepatitis. Proc Natl Acad Sci U S A. 1991;88(10):4186-90.
17. Hadziyannis S, Bramou A, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe-positive chronic hepatitis with replicating B virus. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins 1991:673-6.
18. Naoumov NV, Schneider R, Grotzinger T, Jung MC, Miska S, Pape GR, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992;102(2):538-43.
19. Lai ME, Solinas A, Mazzoleni AP, Deplano A, Farci P, Lisci V, et al. The role of precore hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. J Hepatol 1994;20(6):773-81.
20. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen negative chronic hepatitis B: natural history and treatment. Semin Liver Diseases 2006;26(2):130-41.
21. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48(2):335-52.
22. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45(4):1056-75.
23. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Serum HBV DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002;122(7):2092-93.
24. Seo Y, Yoon S, Truong BX, Kato H, Hamano K, Kato M, et al. Serum hepatitis B virus DNA levels differentiating inactive carriers from patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005;17(7):753-7.
25. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47(6):760-76.